Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2025-12-27 @ 11:02 PM
Study NCT ID:
NCT06077760
Status:
RECRUITING
Last Update Posted:
2025-12-18
First Post:
2023-10-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-06
Start Date Type:
ACTUAL
Primary Completion Date:
2030-06-25
Primary Completion Date Type:
ESTIMATED
Completion Date:
2035-12-21
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-05
First Submit QC Date:
None
Study First Post Date:
2023-10-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-17
Last Update Post Date:
2025-12-18
Last Update Post Date Type:
ESTIMATED